Navigation Links
Telik Announces Third Quarter 2012 Financial Results
Date:11/9/2012

PALO ALTO, Calif., Nov. 9, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $1.9 million, or $0.78 per share, for the third quarter ended September 30, 2012, compared with a net loss of $2.8 million, or $1.58 per share (adjusted for the 1-for-30 reverse split of the company's common stock effected on March 30, 2012), for the comparable period in 2011.

For the quarter ended September 30, 2012, total operating costs and expenses were $1.9 million, compared with $2.9 million in the third quarter of 2011. Operating expenses in the 2012 third quarter included stock-based compensation expense of approximately $0.1 million. Operating expenses were approximately 34% lower in the third quarter of 2012 compared with the same period in 2011, primarily due to lower headcount, corporate and stock-based compensation expenses.

For the nine months ended September 30, 2012, Telik reported a net loss of $6.2 million, or $3.07 per share, compared with a net loss of $9.5 million, or $5.30 per share, for the same period in 2011.  Total operating expenses for the first nine months of 2012 were $6.2 million, compared with $9.6 million for the same period in 2011. Operating expenses in the first nine months of 2012 included approximately $0.6 million in stock-based compensation expense. The reduction in operating expenses of approximately 35% in the first nine months of 2012 compared with the same period in 2011 was primarily due to lower headcount, reduced clinical trial expenses, and lower corporate and stock-based compensation expenses.

At September 30, 2012, Telik had $6.6 million in cash, cash equivalents and investments including restricted investments, compared to $11.7 million at December 31, 2011. In order to meet its current cash requirements beyond the first quarter of 2013, the company will have to raise additional funds through corporate partnering or equity financings. Although the company has been able to raise funds through its At Market Issuance Sales Agreement, there is no assurance Telik will be successful in obtaining additional funding in the near future.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.Telik, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months EndedSeptember 30,September 30,2012201120122011Operating costs and expenses:Research and development 

$
867$
,305$
2,788$
4,464General and administrative 

1,0111,5503,4235,090Total operating costs and expenses

1,8782,8556,2119,554Loss from operations

(1,878)(2,855)(6,211)(9,554)Interest and other income (expense), net

27631Net loss

$
(1,876)$
(2,848)$
(6,205)$
(9,523)Basic and diluted net loss per share*

$
(0.78)$
(1.58)$
(3.07)$
(5.30)Weighted average shares used to calculate basic and diluted net loss per share*

2,3951,7992,0211,796* Adjusted for the 1-for-30 reverse stock splitSelected Balance Sheet Data(In thousands)(Unaudited)September 30,December 31,20122011Cash, cash equivalents, investments and restricted investments

$
,642$
,700Total assets

7,44512,412Stockholders' equity

4,6278,299
'/>"/>

SOURCE Telik, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
2. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
3. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
4. IntelliCell BioSciences Announces FDA Registration for its Cell Processing Facility
5. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
6. Unilife Corporation Announces Financial Results For Fiscal Year 2013 First Quarter
7. Array BioPharma Announces Proposed Public Offering Of Common Stock
8. Allscripts Announces Third Quarter 2012 Results
9. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
10. Protalex, Inc. Announces Screening Of First Patients In U.S. For New Trial Of PRTX-100 In Patients With Active Rheumatoid Arthritis
11. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017 ITL Limited, ( ASX: ITD ), an ... the half year ended 31 December 2016 compared with the previous ... can be viewed here . Highlights ... up 104%) Earnings per share of 2.2 cents ... $17.5m (Dec 2015: $15.7m; up 11%) Profit before ...
(Date:2/23/2017)... 23. Februar 2017 Im Rahmen seiner ... Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, 2017 mit dem ... Innovationsplattform aktiv an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. ... Continue Reading ... ...
(Date:2/23/2017)... , Feb. 23, 2017 AcelRx ... focused on the development and commercialization of innovative ... announced that it will release fourth quarter and ... March 2nd, 2017. AcelRx management will host an ... (1:30 p.m. Pacific Time) on March 2 nd ...
Breaking Medicine Technology:
(Date:2/26/2017)... , ... February 26, 2017 , ... IndustryArchive.Org . ... with Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales ... the founder of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling ...
(Date:2/25/2017)... (PRWEB) , ... February 25, 2017 , ... FCPX users ... Color tools from Pixel Film Studios. With ProSharpen Color users have total control over ... easily refine their color range. With color spectrum tools users can visually see the ...
(Date:2/24/2017)... Pittsburgh, PA (PRWEB) , ... February 24, 2017 , ... ... by researchers at the University of Pittsburgh points to eight genes that may explain ... the other, according to the results of a study published today in the journal ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Healthcare Associates ... Medical Center at Craig Ranch building at 8080 State Highway 121, Suite 210, McKinney, ... with easy access to Highway 121. , As the practice has grown, the need ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
Breaking Medicine News(10 mins):